Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy

被引:29
|
作者
Ko, Na Re [1 ,2 ]
Van, Se Young [1 ,2 ]
Hong, Sung Hwa [3 ]
Kim, Seog-Young [4 ]
Kim, Miran [2 ]
Lee, Jae Seo [5 ]
Lee, Sang Ju [2 ]
Lee, Yong-kyu [6 ]
Kwon, Il Keun [5 ]
Oh, Seung Jun [2 ]
机构
[1] Asan Inst Life Sci, Biomed Res Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Nucl Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[3] Univ Toronto, Dept Chem Engn & Appl Chem, 200 Coll St, Toronto, ON M5S 3E5, Canada
[4] Univ Ulsan, Coll Med, Dept Convergence Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[5] Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae Ro, Seoul 02447, South Korea
[6] Korea Natl Univ Transportat, Dept Chem & Biol Engn, 50 Daehak Ro, Cheongju, South Korea
基金
新加坡国家研究基金会;
关键词
stimuli-responsive degradation system; glutathione; breast cancer; Herceptin; active targeting; PEGylation; IN-VITRO; NONCOVALENT PEGYLATION; 1ST-LINE TREATMENT; PHASE-II; TRASTUZUMAB; OXIDE; CHEMOTHERAPY; DELIVERY; GLUTATHIONE; NANOMATERIALS;
D O I
10.3390/nano10010091
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Dual stimuli-responsive degradable carbon-based nanoparticles (DS-CNPs) conjugated with Herceptin (HER) and polyethylene glycol (PEG) have been designed for the treatment of HER2-positive breast cancer. Each component has been linked through disulfide linkages that are sensitive to glutathione in a cancer microenvironment. beta-cyclodextrin (beta-CD) on the surface of DS-CNPs formed an inclusion complex (DL-CNPs) with doxorubicin (DOX) at a high loading capacity of 5.3 +/- 0.4%. In response to a high level of glutathione (GSH) and low pH in a tumor environment, DL-CNPs were rapidly degraded and released DOX in a controlled manner via disruption of host-guest inclusion. These novel DL-CNPs exhibited high cellular uptake with low toxicity, which induced the efficient inhibition of antitumor activity both in vitro and in vivo. Cell viability, confocal laser scanning microscopy, and animal studies indicate that DL-CNPs are a great platform with a synergistically enhanced antitumor effect from the dual delivery of HER and DOX in DL-CNPs.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Glutathione-responsive PEGylated GQDs as theranostic agents of HER2-positive breast cancer
    Ko, N. R.
    NEW BIOTECHNOLOGY, 2018, 44 : S96 - S96
  • [2] Developing a fluorescence immunosensor for detection of HER2-positive breast cancer based on graphene and magnetic nanoparticles
    Digehsaraei, Sepideh Yektaniroumand
    Salouti, Mojtaba
    Amini, Bahram
    Mahmazi, Sanaz
    Kalantari, Mohsen
    Kazemizadeh, Alireza
    Mehrvand, Jamshid
    MICROCHEMICAL JOURNAL, 2021, 167
  • [3] Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast
    Sun, Jin-Zhong
    Chen, Chuang
    Jiang, Guan
    Tian, Wei-Qun
    Li, Yan
    Sun, Sheng-Rong
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 : 1339 - 1346
  • [4] Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy
    Zhang, Xuejing
    Niu, Shiwei
    Williams, Gareth R.
    Wu, Jianrong
    Chen, Xia
    Zheng, Hong
    Zhu, Li-Min
    CARBOHYDRATE POLYMERS, 2019, 221 : 84 - 93
  • [5] Ultrasonic-responsive piezoelectric stimulation enhances sonodynamic therapy for HER2-positive breast cancer
    Chen, Zhiguang
    Yang, Lizhi
    Yang, Zhimin
    Wang, Zihua
    He, Wen
    Zhang, Wei
    JOURNAL OF NANOBIOTECHNOLOGY, 2024, 22 (01)
  • [6] HER2-positive Breast Cancer: MRI-based Optimization of Neoadjuvant Therapy
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 666 - 666
  • [7] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [8] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [9] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
    Church, David N.
    Price, Chris G. A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
  • [10] Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells
    Shen, Yinxing
    Zhang, Junqi
    Hao, Weiju
    Wang, Tong
    Liu, Jing
    Xie, Youhua
    Xu, Shouhong
    Liu, Honglai
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 537 - 553